Fig. 1 · Structure

Documents & Downloads

Magnolol

Cat. No. A10551 CAS 528-43-8
Magnolol (2,2'-Bichavicol) is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PPARγ EC50 17.7 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 45 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 32416457]
A549 IC50 > 5 μg/mL Cytotoxicity against human A549 cells by MTT assay [PMID: 17918910]
A549 IC50 > 80 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay [PMID: 32044229]
A549 IC50 > 80 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 32791403]
A549 IC50 57.36 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 30006164]
A549 IC50 82.4 μM Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 33069436]
AGS IC50 > 45 μM Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 32416457]
BV-2 IC50 14.9 μg/mL Inhibition of NADPH oxidase-mediated ROS production in LPS-stimulated mouse BV2 cells after 20 mins by flow cytometry [PMID: 19086868]
CHO EC50 18.3 μM Partial agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940 [PMID: 24900561]
CHO EC50 3.28 μM Partial agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940 [PMID: 24900561]
HCC827 IC50 > 40 μM Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay [PMID: 30006164]
HCC827 IC50 94.65 μM Antiproliferative activity against human HCC827 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 33069436]
HEK293 IC50 > 80 μM Antiproliferative activity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 32791403]
HeLa IC50 > 5 μg/mL Cytotoxicity against human HeLa cells by MTT assay [PMID: 17918910]
HeLa IC50 > 80 μM Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 32791403]
HepG2 IC50 > 45 μM Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 32416457]
HepG2 2.2.15 IC50 2.03 μM Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA [PMID: 23434030]
HepG2 2.2.15 IC50 3.76 μM Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA [PMID: 23434030]
HepG2 2.2.15 CC50 63.68 μM Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay [PMID: 23434030]

19 records · Scroll to view more

Magnolol Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Magnolol from 3 published references. In vitro models include CT26; A431 cells.

Magnolol In Vitro Studies

Magnolol was evaluated using MTT cell viability assays in CT26 and A431 cells. The reported IC50 in CT26 and HT29 cells was around 75 μM at 24 h. In A431 cells treated with Magnolol, viability relative to controls ranged from 80 - 50% at 48 h. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Magnolol and Cell Viability in Colon Cancer Cells

Cell-based study · CT26 [1]

CT26 cells were treated with Magnolol and evaluated using an MTT cell viability assay. The reported IC50 in CT26 and HT29 cells was around 75 μM at 24 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell Viability (MTT Assay)IC50 around 75 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 25, 50, 75, 100 μM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Magnolol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. Magnolol Suppressed Tumor Cell Growth, PKC/NF-κB Signaling, Expression of NF-κB Mediated Downstream Proteins in CRC Cells (S11); 4. Materials and Methods > 4.3. Cell Viability (MTT Assay) (S62, S63); Figure 2 legend (S128)

Cell Viability (MTT Assay): Cell Viability (MTT Assay); comparator: 0 μM magnolol — 2. Results > 2.2. Magnolol Suppressed Tumor Cell Growth, PKC/NF-κB Signaling, Expression of NF-κB Mediated Downstream Proteins in CRC Cells (S11); 4. Materials and Methods > 4.3. Cell Viability (MTT Assay) (S62)

Magnolol and Cell Viability in Epidermoid Carcinoma Cells

Cell-based study · A431 cells (9000 cells/well) [2]

A431 cells were treated with Magnolol at 75, 100, 125 μM and evaluated using an MTT assay. Cell viability relative to controls ranged from 80 - 50% at 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was determined at the end of each treatment by using MTT assaycell viability 80 - 50%[2]

Literature-Reported Treatment Conditions

Treatment concentration
75, 100, 125 μM
Exposure duration
48 h
Method
this stock solution was diluted in DMEM at different concentrations and was immediately used
Vehicle
0.4% DMSO
Methods and source locations

Compound reported in the paper: Magnolol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell culture (S10); Methods > MTT assay for cell viability (S30, S31, S32); Results > Magnolol treatment decreased cell viability in A431 cells (S97)

Cell viability was determined at the end of each treatment by using MTT assay: Cell viability was determined at the end of each treatment by using MTT assay; comparator: growth medium 0.4% DMSO — Methods > MTT assay for cell viability (S32); Results > Magnolol treatment decreased cell viability in A431 cells (S97)

Magnolol In Vivo Studies

BALB/c male nude mice bearing SH-SY5Y xenografted tumors received Magnolol at 35 mg/kg by intraperitoneal injection once-daily for 30 days. Tumor growth was significantly reduced by 32.81% in the Magnolol-treated group compared with saline controls. [3]

Magnolol and Tumor Growth in a Neuroblastoma Xenograft Model

Animal study · BALB/c male nude mice; SH-SY5Y xenografted tumors; n = 8 [3]

BALB/c male nude mice bearing SH-SY5Y xenografted tumors received Magnolol by intraperitoneal injection at 35 mg/kg for 30 days. Tumor growth was significantly reduced by 32.81% compared with the saline control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumestumor growth 32.81%[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
once-daily; for 30 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Magnolol 35 mg/kgsaline (Ctrl)the growth of tumors was significantly reduced by 32.81% (control vs. magnolol-treatment)[3]
Magnolol 35 mg/kg
Model: BALB/c male nude mice; SH-SY5Y xenografted tumors; n = 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Magnolol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mouse xenograft model (S54, S56, S58); Results > Magnolol elicits cytotoxicity in cancer cells and inhibits tumor growth in vivo (S229, S230, S232, S244, S246)

Tumor volumes: Tumor volumes; comparator: saline (Ctrl) — Results > Magnolol elicits cytotoxicity in cancer cells and inhibits tumor growth in vivo (S232, S246)

Magnolol 35 mg/kg · Materials and methods > Mouse xenograft model (S58); Results > Magnolol elicits cytotoxicity in cancer cells and inhibits tumor growth in vivo (S230, S244, S246)

Specifications

Manufacturer Adooq Bioscience
CAS Number 528-43-8
Formula C18H18O2
Molecular Weight 266.3
Synonyms 2,2'-Bichavicol
SMILES
C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 46 mg/mL (172.72 mM)
Water Insoluble
Ethanol 46 mg/mL (172.72 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Magnolol Research References

  1. [1] Su CM, Weng YS, Kuan LY, et al. Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo. Int J Mol Sci (2020). PMID: 32429376 DOI: 10.3390/ijms21103527 Source material
  2. [2] Chilampalli C, Guillermo R, Zhang X, et al. Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. BMC Cancer (2011). PMID: 22014088 DOI: 10.1186/1471-2407-11-456 Source material
  3. [3] Tang Y, Wang L, Yi T, et al. Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy. Acta Pharm Sin B (2021). PMID: 35024319 DOI: 10.1016/j.apsb.2021.06.007 Source material

Added to your cart

View Cart Checkout
Loading...